Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Payables (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Payables data on record, last reported at $63.1 million in Q1 2026.

  • On a quarterly basis, Payables rose 207.4% to $63.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $63.1 million, a 207.4% increase, with the full-year FY2025 number at $70.9 million, up 46.34% from a year prior.
  • Payables reached $63.1 million in Q1 2026 per PCVX's latest filing, down from $70.9 million in the prior quarter.
  • Over the last five years, Payables for PCVX hit a ceiling of $70.9 million in Q4 2025 and a floor of $4.8 million in Q1 2022.
  • A 5-year average of $24.6 million and a median of $16.3 million in 2023 define the central range for Payables.
  • Peak YoY movement for Payables: crashed 84.93% in 2022, then soared 232.16% in 2024.
  • Tracing PCVX's Payables over 5 years: stood at $9.8 million in 2022, then skyrocketed by 48.92% to $14.6 million in 2023, then skyrocketed by 232.16% to $48.5 million in 2024, then soared by 46.34% to $70.9 million in 2025, then decreased by 11.06% to $63.1 million in 2026.
  • Business Quant data shows Payables for PCVX at $63.1 million in Q1 2026, $70.9 million in Q4 2025, and $49.0 million in Q3 2025.